HAL (France)
open access
A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic
Abstract The COVID-19 pandemic caused by the SARS-CoV-2 virus remains a global public health crisis. Although widespread vaccination campaigns are underway, their efficacy is reduced owing to emerging variants of concern 1,2 . Development of host-directed therapeutics and prophylactics could limit s
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Editorial: Deciphering the T cell response in SARS-CoV-2 infection#250590
- Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19)#901891
- Effectiveness of COVID-19 Vaccines Against the SARS-COV-2 Delta (B.1.617.2)#914321
- Repurposing Candidate Drugs to Prevent SARS-CoV-2: A PharmLines Test-Negative Case–Control Study.#317955
- Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)#481788
Record · ID 1235254
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive